Dissolve Strips ™ (sublingual cannabis wafers) Now Out there to Aurora’s Canadian Healthcare Sufferers
NYSE | TSX: ACB OTC: CTTH
EDMONTON and HAMILTON, ON, Oct. eight, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian business defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC | CTTH) announced now the productive commercialization of CTT’s cannabinoid-infused sublingual wafers. The new cannabis item line, a very first of its sort, has been launched by Aurora in the Canadian healthcare cannabis market place beneath the brand name “Dissolve Strips™”.
Aurora has an ownership interest in CTT of about 9%, with a warrant permitting it to improve its stake to 42.five%, and access to CTT’s sublingual cannabis wafers drug delivery technologies, which is patent protected or patent pending in a number of jurisdictions.
Terry Booth, CEO of Aurora stated:
“Aurora’s Dissolve Strips™ provide one of a kind positive aspects more than other ingestible solutions due to their ease of administration, discrete nature and precise dosage, that offers additional speedy bioavailability of cannabinoids by way of sublingual use. This adds however yet another revolutionary supplying to our increasing portfolio of higher good quality, healthcare solutions that we provide our patient base, and is testament to our sector major capacity to perform with technologies partners and regulators to bring new type variables to market place quickly.”
CTT’s CEO Cam Birge, added:
“The item launch with Aurora of the Dissolve Strips™ is a important milestone for us that marks the transition of CTT from a technologies improvement phase to a income producing phase. This is the culmination of years of really hard perform by our founder Dr. Modi and the complete CTT and Aurora item improvement teams. We are pretty proud of this co-achievement and congratulate Aurora for the considerable efforts and item enhancements to bring Dissolve Strips™ (sublingual cannabis wafers) to the cannabis market place. Our sights, even so, are set significantly greater. The subsequent stage in our improvement will be the launch of a broader portfolio of one of a kind solutions on a worldwide scale. We have been functioning towards this, and I appear forward to reporting on our progress in the coming quarters.”
Orally Dissolvable Thin Film (“ODF”) Wafers (“wafers” or “sublinguals”) are a proprietary drug delivery mechanism in the type of paper-thin polymer films made use of as carriers for pharmaceutical agents that have the following added benefits:
- ODF Wafer is taken orally but does not need water or swallowing
- ODF Wafers dissolve promptly in the oral cavity (five-15 seconds), with the active ingredient quickly absorbed and diffused for direct access to the bloodstream.
- The active ingredient, as soon as absorbed, can bypass the liver’s very first-pass impact, enhancing therapeutic outcomes and efficacy via enhanced bioavailability, and facilitates great patient compliance.
- ODF Wafers are appropriate for a wide variety of sufferers, such as geriatric and pediatric sufferers who encounter difficulty swallowing.
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 nations across 5 continents, Aurora is one particular of the world’s biggest and major cannabis organizations. Aurora is vertically integrated and horizontally diversified across just about every crucial segment of the worth chain, from facility engineering and design and style to cannabis breeding and genetics study, cannabis and hemp production, derivatives, higher worth-add item improvement, household cultivation, wholesale and retail distribution.
Hugely differentiated from its peers, Aurora has established a uniquely sophisticated, constant and effective production approach, primarily based on objective-constructed facilities that integrate major-edge technologies across all processes, defined by comprehensive automation and customization, resulting in the huge scale production of higher-good quality constant item. Made to be replicable and scalable globally, our production facilities are created to make cannabis at substantial scale, with higher good quality, sector-major yields, and low-per gram production fees. Every of Aurora’s facilities is constructed to meet European Union Fantastic Manufacturing Practices (“EU GMP“) requirements. Certification has been granted to Aurora’s very first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European healthcare cannabis distributor Aurora Deutschland. All Aurora facilities are created and constructed to the EU GMP common.
In addition to the Company’s speedy organic development and powerful execution on strategic M&A, which to date consists of 17 wholly owned subsidiary companies–
- Peloton Pharmaceutical
- Aurora Deutschland
- H2 Biopharma
- BC Northern Lights
- Larssen Greenhouses
- CanniMed Therapeutics
- HotHouse Consulting
- MED Colombia
- ICC Labs
- Chemi Pharmaceutical
Aurora is distinguished by its reputation as a companion and employer of option in the worldwide cannabis sector, getting invested in and established strategic partnerships with a variety of major innovators, such as: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), Higher Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).
Aurora’s Frequent Shares trade on the TSX and NYSE beneath the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.
For additional info about Aurora, please go to our investor web page, investor.auroramj.com
About CTT Pharmaceutical
CTT’s principal asset is a one of a kind and novel patented drug delivery technologies, an orally administered, rapid dissolving thin film (the “Wafer”). This technologies platform will target each the human and veterinarian (pet) markets for remedy of a lot of ailments. The Organization believes that its Wafer technologies will be one particular of the very first to achieve use in important markets such as discomfort management. Many Canadian and U.S. patents guard the Oral Thin Film (Sublingual Cannabis Wafer) formulation.
CTT’s oral rapid dissolving drug delivery systems consist of edible Wafers. These wafers dissolve without having water and inside a handful of seconds following placement in the mouth. The majority of drugs administered utilizing our drug delivery method mirror injections as:
- They have the capacity to enter the bloodstream promptly
- They are handy and discreet
- And they can be administered anyplace
A quicker absorption price is accomplished for the reason that the mouth consists of a pretty thin mucosa and is very vascular.
There is no bitter taste, no smoke inhalation, much less degradation of medication (by bypassing the stomach). And most importantly, reduce dosage units are expected offered the efficacy of absorption. Patient compliance is also enhanced specially with these who have a worry of choking or difficulty swallowing, and/or are pediatric, geriatric or incapacitated.
For additional info, please go to our web page: www.cttpharmaceuticals.com
|Terry Booth, CEO||Cam Birge, CEO|
|Aurora Cannabis Inc.||CTT Pharmaceutical Holdings Inc.|
Supply Aurora Cannabis Inc.